Company Milestones
Founding & Early R&D
Founded in Menlo Park with a mission to improve healthcare through ultra-high-resolution disease detection, starting with ‘half a bench’ at the StartX incubator. Received an NIH grant for the first single-gene NIPT clinical study with Baylor University and transitioned to our first independent lab with six employees.
Market Validation & Series A
Closed a $15M Series A funding round and secured CLIA certification, marking the transition from a research startup to a commercial-stage molecular diagnostics company. Launched the first UNITY test and successfully processed our first commercial patient sample.
Commercial Launch & Scale
Launched UNITY Fetal Risk™ Screen, the first and only prenatal test that can assess fetal risk for common recessive conditions using only a maternal blood sample, addressing a significant gap in the traditional NIPT market. Closed a $55M Series B to accelerate commercial growth.
Rigor & Clinical Validation
Closed a $125M Series C and demonstrated technical leadership through CAP Accreditation and landmark data in Genetics in Medicine and the American Journal of Hematology. These studies, plus a large-scale evaluation in Prenatal Diagnosis, confirmed the high accuracy of single-gene NIPT in the general pregnancy population. This rigor supported the launch of the UNITY Fetal Antigen™ test and a Phase 3 clinical trial collaboration with Johnson & Johnson.
Oncology Expansion
Launched Northstar Select® and Northstar Response®, applying our proprietary smNGS platform to liquid biopsy for therapy selection and treatment monitoring for advanced solid tumor cancers.
Hyper-Growth & Scale
Raised $130M in an oversubscribed Series D at $1B+ valuation. Presented the first prospective, head-to-head study for Northstar Select® at ASCO 2024, demonstrating the ability to uncover ~50% more clinically actionable alterations compared to standard NGS. Expanded the workforce to 500+ employees to meet surging demand.
Maturity & Public Debut
Surpassed 1 million UNITY tests and secured MolDx approval for Northstar Select®, facilitating expanded Medicare access. Our public listing marked a foundational step in our aspiration to become a cornerstone of the healthcare market and to join the S&P 500.
Key Investors
